Aethlon Medical (AEMD) CEO Note: Cancer Treatment Discovery, Exosomes Transport Pharmaceutical Industry Targets
Aethlon Medical, Inc. (OTCQB: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce.
The discovery that our Hemopurifer® captures tumor-secreted exosomes provides hope for a new therapeutic paradigm to augment cancer care. Yes, the same Hemopurifier® we are preparing to advance in a forthcoming FDA approved infectious disease study. In my last CEO note, I referenced a National Institute of Health (NIH) – National Cancer Institute (NCI) sponsored article that referenced Hemopurifier® therapy as a candidate to address tumor-secreted exosomes.
The article detailed several exosomal mechanisms that promote cancer progression, including suppression of the immune system, triggering resistance to cancer therapies, promotion of angiogenesis and seeding the spread of metastasis. The article also indicated that high levels of circulating exosomes correlated with advanced stage cancer.
As researchers continue to unravel the deleterious mechanisms of exosomes underlying cancer, it has become clear that these particles also transport many molecular targets of interest to the pharmaceutical industry. Thus providing further support for a medical device that is able to target circulating exosomes without adding drug toxicity to established cancer therapies.
In this regard, I am pleased to share the following overview authored by Dr. Annette Marleau (our Director of Tumor Immunology), which outlines oncology targets of the pharmaceutical industry that have been reported to be transported by exosomes.